SIRT1 and diabetic kidney disease: Therefore, SIRT1 and SIRT3 show positive effects in a variety of diabetic complications, including DKD, DN, DR, and DCM, which indicated that these two SIRTs could serve as promising therapeutic targets in the clinical treatment of DM-related target organ damage.